{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:39:00Z","timestamp":1771475940409,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40265-015-0448-0","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T09:23:27Z","timestamp":1438680207000},"page":"1523-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Insulin Degludec\/Liraglutide: A Review in Type 2 Diabetes"],"prefix":"10.1007","volume":"75","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"issue":"9 Suppl 1","key":"448_CR1","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2013.06.012","volume":"126","author":"SA Ross","year":"2013","unstructured":"Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38\u201348.","journal-title":"Am J Med"},{"issue":"9961","key":"448_CR2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228\u201334.","journal-title":"Lancet"},{"issue":"10 Suppl","key":"448_CR3","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.amjmed.2014.07.006","volume":"127","author":"C Sorli","year":"2014","unstructured":"Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med. 2014;127(10 Suppl):S39\u201348.","journal-title":"Am J Med"},{"issue":"6","key":"448_CR4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care"},{"issue":"18","key":"448_CR5","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-014-0325-2","volume":"74","author":"NW Carris","year":"2014","unstructured":"Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. 2014;74(18):2141\u201352.","journal-title":"Drugs"},{"issue":"1","key":"448_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4239\/wjd.v5.i1.40","volume":"5","author":"B Ahr\u00e9n","year":"2014","unstructured":"Ahr\u00e9n B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014;5(1):40\u201351.","journal-title":"World J Diabetes"},{"issue":"3","key":"448_CR7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1185\/03007995.2013.852078","volume":"30","author":"R Goldenberg","year":"2013","unstructured":"Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2013;30(3):431\u201345.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"448_CR8","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/14712598.2014.904851","volume":"14","author":"A Kumar","year":"2014","unstructured":"Kumar A. Insulin degludec\/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther. 2014;14(6):869\u201378.","journal-title":"Expert Opin Biol Ther"},{"key":"448_CR9","unstructured":"Novo Nordisk A\/S. Xultophy 100 units\/mL\u00a0+\u00a03.6\u00a0mg\/mL solution for injection: EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 21 Jul 2015."},{"issue":"6","key":"448_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-013-0051-1","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Insulin degludec and insulin degludec\/insulin aspart: a review of their use in the management of diabetes mellitus. Drugs. 2013;73(6):575\u201393.","journal-title":"Drugs"},{"issue":"18","key":"448_CR11","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s40265-014-0321-6","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs. 2014;74(18):2161\u201374.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"448_CR12","first-page":"61","volume":"31","author":"J Vora","year":"2014","unstructured":"Vora J, Linjawi S, Gough SC, et al. Improved postprandial glycaemic control in Type 2 diabetes with a combination of insulin degludec and liraglutide: results from a meal test [abstract no. P113]. Diabet Med. 2014;31(Suppl 1):61.","journal-title":"Diabet Med"},{"issue":"11","key":"448_CR13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"448_CR14","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Bode B, Ingwersen SH, et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015. doi: 10.1002\/jcph.549 .","journal-title":"J Clin Pharmacol"},{"key":"448_CR15","unstructured":"Novo Nordisk A\/S. Victoza 6\u00a0mg\/ml solution for injection in pre-filled pen: EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 21 Jul 2015."},{"key":"448_CR16","unstructured":"Novo Nordisk A\/S. Tresiba 100 units\/mL solution for injection in pre-filled pen: EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 21 Jul 2015."},{"issue":"11","key":"448_CR17","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","volume":"37","author":"JB Buse","year":"2014","unstructured":"Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926\u201333.","journal-title":"Diabetes Care"},{"key":"448_CR18","unstructured":"Linjawi S, Bode B, Chaykin LB, et al. Efficacy and safety of IDegLira (combination of insulin degludec\u00a0+\u00a0liraglutide), in insulin-naive patients with T2D uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy [abstract no. 1002-P plus poster]. In: American Diabetes Association 75th Scientific Sessions. 2015."},{"key":"448_CR19","unstructured":"Rodbard HW, Bode B, Harris SB, et al. IDegLira in insulin-naive patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV study [abstract no. 1003-P plus poster]. In: American Diabetes Association 75th Scientific Sessions. 2015."},{"key":"448_CR20","doi-asserted-by":"crossref","unstructured":"Buse J, P\u00e9rez Manghi FC, Garc\u00eda-Hern\u00e1ndez PA, et al. Insulin degludec\/liraglutide (IDegLira) is superior to insulin glargine (IG) in A1c reduction, risk of hypoglycemia, and weight change: DUAL V study [abstract no. 166-OR]. In: American Diabetes Association 75th Scientific Sessions. 2015.","DOI":"10.1007\/s12467-015-0044-7"},{"key":"448_CR21","author":"SC Gough","year":"2015","unstructured":"Gough SC, Bode B, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015. doi: 10.1111\/dom.12498 .","journal-title":"Diabetes Obes Metab"},{"key":"448_CR22","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01676116. 2012. http:\/\/www.clinicaltrials.gov . Accessed 21 Jul 2015."},{"key":"448_CR23","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01952145. 2013. http:\/\/www.clinicaltrials.gov . Accessed 21 Jul 2015."},{"key":"448_CR24","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01618162. 2012. http:\/\/www.clinicaltrials.gov . Accessed 21 Jul 2015."},{"issue":"Suppl 1","key":"448_CR25","first-page":"S338","volume":"57","author":"HW Rodbard","year":"2014","unstructured":"Rodbard HW, Buse JB, Woo VC, et al. Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes [abstract no. 835]. Diabetologia. 2014;57(Suppl 1):S338\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"448_CR26","first-page":"A18","volume":"63","author":"JB Buse","year":"2014","unstructured":"Buse JB, Rodbard HW, Woo VC, et al. Impact of BMI on HbA1c reduction, hypoglycemia rates, and insulin requirements in response to IDegLira in patients with type 2 diabetes (T2D) [abstract no. 66-OR]. Diabetes. 2014;63(Suppl 1):A18.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"448_CR27","first-page":"S339","volume":"57","author":"T Vilsboll","year":"2014","unstructured":"Vilsboll T, Vora J, Jarlov H, et al. IDegLira, a combination of insulin degludec and liraglutide, enables patients with type 2 diabetes to reach target glycaemic control faster than its individual components alone [abstract no. 836 plus poster]. Diabetologia. 2014;57(Suppl 1):S339.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"448_CR28","first-page":"S108","volume":"57","author":"A King","year":"2014","unstructured":"King A, Philis-Tsimikas A, Langbakke IH, et al. IDegLira, a combination of insulin degludec and liraglutide, improves both pre- and postprandial plasma glucose in patients with type 2 diabetes [abstract no. 243]. Diabetologia. 2014;57(Suppl 1):S108\u20139.","journal-title":"Diabetologia"},{"key":"448_CR29","unstructured":"King AB, Philis-Tsimikas A, Kilpatrick ES, et al. Assessment of glycemic control by CGM in patients with T2D treated with IDegLira [abstract no. 170-OR]. In: American Diabetes Association 75th Scientific Sessions. 2015."},{"key":"448_CR30","unstructured":"Linjawi S, Brod M, Bode B, et al. In insulin-naive patient with T2DM uncontrolled on GLP-1 receptor agonists (GLP-1RA), IDegLira (novel combination of insulin degludec\u00a0+\u00a0liraglutide) resulted in improved patient-reported outcomes vs. unchanged GLP-1RA [abstract no. 1150-P plus poster]. In: American Diabetes Association 75th Scientific Sessions. 2015."},{"key":"448_CR31","unstructured":"Aroda VR, Jaeckel E, Jarlov H, et al. Incidence of gastrointestinal side effects similar between IDegLira and non-GLP-1RA comparators [abstract no. 1009-P plus poster]. In: American Diabetes Association 75th Scientific Sessions. 2015."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0448-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0448-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T01:44:38Z","timestamp":1567043078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0448-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0448-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}